Passage Bio’s PBGM01 receives Orphan Drug Designation from EMA for treatment of GM1 Gangliosidosis

▴ Passage Bio’s PBGM01 receives Orphan Drug Designation from EMA for treatment of GM1 Gangliosidosis
European Commission (EC) has granted orphan drug designation for the company’s lead gene therapy candidate PBGM01

Passage Bio, Inc., a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that the European Commission (EC) has granted orphan drug designation for the company’s lead gene therapy candidate PBGM01 for the treatment of GM1 gangliosidosis (GM1). PBGM01, an adeno-associated virus (AAV)-delivery gene therapy, has previously been granted Orphan Drug Designation and Rare Pediatric Disease Designation by the U.S. Food and Drug Administration (FDA) for the treatment of GM1. GM1 is a rare and often life-threatening central nervous system disorder with no approved disease-modifying therapies available.

“GM1, most common and severe in infants, results in rapid neurodegeneration and is simply devastating for patients and their families,” said Bruce Goldsmith, Ph.D., president and chief executive officer of Passage Bio. “PBGM01 is a potentially transformative gene therapy that may lead to the preservation of neurological function and an improvement in developmental potential and survival in patients with GM1. Receiving orphan drug designation for PBGM01 in the European Union is an important milestone that will propel our efforts to bring this much-needed therapy to waiting patients.”

The EC grants orphan drug designation based on a positive opinion issued by the EMA Committee for Orphan Medicinal Products (COMP). To qualify for orphan designation, an investigational medicinal product must be intended to treat a chronically debilitating or life-threatening condition that affects fewer than five in 10,000 people across the European Union and there is no effective treatment approved in EU. With EMA orphan drug designation, Passage Bio will receive certain benefits and incentives including 10-year market exclusivity for the approved therapeutic indication once PBGM01 receives marketing authorization as well as clinical protocol assistance and reduced regulatory fees.

Passage Bio expects to initiate dosing of PBGM01 in a Phase 1/2 trial late in the fourth quarter of 2020 or early in the first quarter of 2021, with initial 30-day safety and biomarker data expected in the late first half of 2021. The trial will be an open-label, dose escalation study of PBGM01 administered by a single injection into the intra cisterna magna, or ICM, in pediatric subjects with infantile GM1.

About GM1

GM1 gangliosidosis (GM1) is a rare and often life-threatening monogenic recessive lysosomal storage disease caused by mutations in the GLB1 gene, which encodes lysosomal acid beta-galactosidase (β-gal). Reduced β-gal activity results in the accumulation of toxic levels of GM1 ganglioside in neurons throughout the brain, causing rapidly progressing neurodegeneration. GM1 manifests as a continuum of disease and is most severe in the Infantile form, which is characterized by onset in the first 6 months of life with hypotonia (reduced muscle tone), progressive CNS dysfunction, and rapid developmental regression. Life expectancy for infants with GM1 is two to four years, and infantile GM1 represents approximately 62.5% of the incidence of 0.5 to 1 in 100,000 live births.

Tags : #EuropeanCommissionApproval #OrphanGrugDesignationLatestNewsOct27 #LatestGenetherapyNewsOct27 #PBGM01 #LatestTreatmentForGagliosidosis #PassageBio #LatestPharmaNewsUpdateOct27

About the Author

Team Medicircle

Related Stories

Loading Please wait...

Trending Now

Covid technical Advisory panel advises Karnataka health dept to be prepared for 2nd wave of COVID-19 pandemicDecember 04, 2020
Telangana reports 631 fresh cases of COVID-19December 04, 2020
Odisha crosses milestone in conducting over 6 million tests for COVID-19December 04, 2020
New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary EndpointDecember 04, 2020
Shape Therapeutics Unveils AAVid™ Capsid Discovery Platform and Identification of Novel Tissue-Specific AAV Variants, Solving a Fundamental Delivery Challenge in Gene TherapyDecember 04, 2020
ReAlta Life Sciences Announces EMA Orphan Drug Designation for RLS-0071 for the Treatment of Neonatal EncephalopathyDecember 04, 2020
I2O Therapeutics receives strategic investment from Colorcon VenturesDecember 04, 2020
Study shows personalized provider navigation using machine intelligence may reduce post-surgical hospitalizations and lower costsDecember 04, 2020
Zydus receives approval from DCGI to commence Phase III clinical trials with Pegylated Interferon alpha-2b in India December 04, 2020
PharmaEngine, Inc. collaborates with Sentinel Oncology for SOL-578, a Chk1 inhibitorDecember 04, 2020
Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND ApplicationDecember 04, 2020
1450 new cases of COVID-19 reported in Madhya PradeshDecember 04, 2020
COVID-19 recovery rate in country improves to 94.20 pctDecember 04, 2020
Over 11,70,000 samples tested for COVID-19 across country in last 24 hoursDecember 04, 2020
Britain to cover COVID-19 vaccine side-effects under damages schemeDecember 04, 2020
India’s Active Caseload further dips to 4.35% of Total CasesDecember 04, 2020
COVID-19 recovery rate in Bihar improves to 97.12 pctDecember 04, 2020
Gujarat records 1540 new cases of COVID-19December 04, 2020
Catalyst Biosciences receives FDA Fast track designation for subcutaneous MarzAADecember 04, 2020
AbbVie and Frontier Medicines establish global partnership for research and developmentDecember 04, 2020